|Pregnancy cat.||C (US)|
|(what is this?)|
The drug is patent free.
Early clinical trials showed that a once-a-day dosage was effective. It was subsequently clinically shown to be equally effective as artemether/lumefantrine ("Coartem"), although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.
- "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available". 080218 dndi.org
- "ASAQ - The $1 Future of Malaria Treatment « GlobaLab". 080218 globalab.wordpress.com
- Ndiaye (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. Retrieved 18 January 2013.
- Nidiaye. "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. Retrieved 18 January 2013.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|